Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $81.14

Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) have been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $81.1429.

Several research analysts have commented on AKRO shares. Cowen started coverage on Akero Therapeutics in a report on Monday, August 4th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Akero Therapeutics in a report on Saturday, September 27th. TD Cowen started coverage on Akero Therapeutics in a report on Monday, August 4th. They set a “buy” rating and a $76.00 target price on the stock. Wall Street Zen raised Akero Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright initiated coverage on Akero Therapeutics in a report on Thursday, September 4th. They set a “buy” rating and a $72.00 target price on the stock.

Insiders Place Their Bets

In other news, insider Timothy Rolph sold 12,500 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $44.17, for a total value of $552,125.00. Following the transaction, the insider directly owned 167,124 shares of the company’s stock, valued at $7,381,867.08. The trade was a 6.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jonathan Young sold 12,500 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $46.08, for a total value of $576,000.00. Following the completion of the transaction, the chief operating officer directly owned 197,484 shares in the company, valued at $9,100,062.72. This represents a 5.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 179,253 shares of company stock valued at $8,579,839 over the last 90 days. 7.07% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. acquired a new position in shares of Akero Therapeutics in the 1st quarter valued at about $10,404,000. Ameriprise Financial Inc. acquired a new position in Akero Therapeutics during the 4th quarter worth approximately $422,000. Bank of New York Mellon Corp raised its stake in Akero Therapeutics by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 212,665 shares of the company’s stock worth $8,609,000 after buying an additional 12,235 shares during the period. Allostery Investments LP acquired a new position in Akero Therapeutics during the 1st quarter worth approximately $729,000. Finally, Intech Investment Management LLC raised its stake in Akero Therapeutics by 54.4% during the 1st quarter. Intech Investment Management LLC now owns 58,522 shares of the company’s stock worth $2,369,000 after buying an additional 20,620 shares during the period.

Akero Therapeutics Trading Down 0.7%

Shares of AKRO stock opened at $46.10 on Friday. The firm has a market capitalization of $3.69 billion, a P/E ratio of -23.05 and a beta of -0.29. Akero Therapeutics has a twelve month low of $21.34 and a twelve month high of $58.40. The company has a quick ratio of 12.66, a current ratio of 12.66 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $47.05 and its 200 day simple moving average is $46.63.

Akero Therapeutics (NASDAQ:AKRO) last announced its earnings results on Friday, August 8th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.11. During the same period last year, the company earned ($0.81) EPS. As a group, sell-side analysts predict that Akero Therapeutics will post -3.99 EPS for the current fiscal year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.